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LilBACKGROUND The degree of antiplatelet response to clopidogrel has been associated with clinical outcomes. Studies
have investigated whether adjustment of antiplatelet therapies based on a single platelet function test is beneﬁcial.
OBJECTIVES The aim of the study was to test the stability of platelet reactivity measurements over time among
patients treated with standard and double doses of clopidogrel.
METHODS The ELEVATE–TIMI 56 (Escalating Clopidogrel by Involving a Genetic Strategy–Thrombolysis In Myocardial
Infarction 56) investigators genotyped 333 patients with coronary artery disease and randomized them to various
clopidogrel regimens. Patients with at least 2 platelet function results on the same maintenance dose of clopidogrel
(75 mg or 150 mg) were analyzed. Platelet aggregation was measured using P2Y12 reaction units (PRU).
RESULTS In total, the mean platelet reactivity and the total number of nonresponders (PRU $230) with clopidogrel did
not change between 2 periods for the 75-mg (22.4% vs. 21.9%; p ¼ 0.86) and 150-mg doses of clopidogrel (11.5% vs.
11.5%; p ¼ 1.00). In contrast, when evaluating each patient individually, 15.7% of patients taking clopidogrel 75 mg
and 11.4% of patients taking 150 mg had a change in their responder status when tested at 2 different time points
(p < 0.001). Despite being treated with the same dose of clopidogrel, >40% of patients had a change in PRU >40 on
serial sampling, which approximates the average PRU difference caused by increasing the clopidogrel dose from 75 mg to
150 mg.
CONCLUSIONS Measurements of platelet reactivity vary over time in a signiﬁcant proportion of patients. Thus,
treatment adjustment according to platelet function testing at a single time point might not be sufﬁcient for guiding
antiplatelet therapy in clinical or research settings. (Escalating Clopidogrel by Involving a Genetic Strategy–Thrombolysis
In Myocardial Infarction 56 [ELEVATE–TIMI 56]; NCT01235351) (J Am Coll Cardiol 2014;64:361–8) © 2014 by the
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362T reatment with aspirin and clopido-grel after percutaneous coronaryintervention (PCI) is frequently
used to prevent ischemic complications,
including stent thrombosis (1), and this
approach has been shown to reduce cardio-
vascular events in patients with acute coro-
nary syndromes (ACS) (2). Studies have
demonstrated variability in the pharmacody-
namic response to clopidogrel (3,4). This
variability can be explained in part by ge-netic polymorphisms (5), as well as by demographic,
cellular, and clinical factors (6–9). Some clinical
studies have demonstrated that patients with high
on-clopidogrel platelet reactivity are at increased
risk of stent thrombosis and other major cardiac com-
plications (10–12).SEE PAGE 369Further studies have investigated whether dose
adjustment of clopidogrel can overcome this high
on-treatment platelet reactivity (13–16) and whether
such an adjustment based on platelet function testing
can improve clinical outcomes (17,18). Most of these
studies have used a single platelet function test
result for treatment stratiﬁcation, often obtained
early after the start of antiplatelet treatment with
clopidogrel. Although data have demonstrated that
the mean platelet function across a population is
constant with serial samples (13–15), these ﬁndings
do not exclude signiﬁcant changes among individual
patients over time.
The ELEVATE–TIMI 56 (Escalating Clopidogrel
by Involving a Genetic Strategy–Thrombolysis In
Myocardial Infarction 56) trial investigated the effect
of escalating maintenance doses of clopidogrel on
platelet reactivity in patients with coronary artery
disease, taking into account the cytochrome P450
2C19 (CYP2C19) genotype (16). Participants underwentfees from Bristol-Myers Squibb, Sanoﬁ-Aventis, Eli Lilly, Daiichi-Sa
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received January 2, 2014; revised manuscript received Februaryserial platelet function testing under stable condi-
tions using a point-of-care adenosine diphosphate–
mediated platelet aggregation assay (VerifyNow,
Accumetrics, San Diego, California), as well as a
vasodilator-stimulated phosphoprotein (VASP) assay.
Thus, the study offers an opportunity to assess the
stability of measurements of platelet reactivity over
time in cardiovascular patients treated with standard-
and double-dose clopidogrel in whom clinical factors,
genotype, and compliance have been taken into
account.
METHODS
STUDY POPULATION. ELEVATE–TIMI 56 was a
multicenter, randomized, double-blind trial that
enrolled and genotyped 333 patients across 32 sites
with known cardiovascular disease taking 75 mg of
clopidogrel daily (16). To be eligible, patients had an
indication for the use of clopidogrel (myocardial
infarction and/or PCI $4 weeks and #6 months
before enrollment) and be clinically stable. All
patients took aspirin, 81 to 325 mg daily, and they
were requested to keep taking a stable dose during
the study, if medically appropriate. Key exclusion
criteria were the use of anticoagulants or proton
pump inhibitors, current smoking, previous stent
thrombosis, heightened risk of bleeding, end-stage
renal or hepatic disease, or a procedure or hospital-
ization planned within the next 12 weeks.
The study design and ﬂowof patients for the present
post-hoc analysis are illustrated in Online Figure A. Of
the 333 patients genotyped, 86 patients carried the
CYP2C19*2 loss-of-function polymorphism and were
to be treated with 75, 150, 225, and 300 mg of clopi-
dogrel in various sequences according to the protocol
of the ELEVATE–TIMI 56 trial (16). These individuals
were not included in the present analysis because they
did not have serial platelet function results for thenkyo, The Medicines Company, AstraZeneca, Merck,
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363same dose. The remaining 247 patients did not carry
the CYP2C19*2 loss-of-function polymorphism and
were therefore randomized to a blinded sequence of
maintenance doses of clopidogrel for 4 treatment pe-
riods in various sequences, each w14 days. Two of
these treatment periods were clopidogrel 75 mg and 2
were clopidogrel 150 mg. At the end of each period,
compliance was assessed by pill counting; come-
dication, including aspirin intake, was recorded;
platelet function testing was performed; and clinical
adverse events were ascertained. Patients were
instructed to take their clopidogrel study medication
in the morning, and on the study visit days, they were
instructed to take their dose after blood sampling. In
total, 210 patients had 2 platelet function tests for the
75-mg dose and 209 for the 150-mg dose, along with a
conﬁrmed compliance of >80% at each visit. For the
75-mg dose, 35 patients were excluded due to not
having a second sample at the same dose and 2 due to
compliance <80%; for the 150-mg dose, 36 patients
were excluded due to not having a second sample at
the same dose and 2 due to compliance <80%.
The trial was approved by the institutional review
board of each participating site, and participants
provided written informed consent.
PLATELET FUNCTION STUDIES. Blood samples for
platelet function testing were collected at the trough
level before intake of the next maintenance dose
and w24 h after the last dose of clopidogrel by direct
venipuncture using a 21-gauge (or higher diameter)
needle, taking care to avoid hemolysis or contami-
nation by tissue factors. Samples with signs of he-
molysis or clotting were to be redrawn.
Platelet aggregation testing was conducted at each
site with an encrypted point-of-care device (Ver-
ifyNow P2Y12 test, Accumetrics) and run between 10
min and 4 h after sampling according to manufacturer
instructions. Results were reported as P2Y12 reaction
units (PRU), indicating the amount of adenosine
diphosphate–mediated platelet aggregation. The
prespeciﬁed deﬁnition of nonresponder status was
based on the VerifyNow assay and deﬁned as $230
PRU (19). Because an additional nonresponder deﬁ-
nition of $208 PRU also has been described (20,21),
this cutoff was used in a sensitivity analysis. The
coefﬁcient of variation of this assay in patients
treated with clopidogrel has been previously reported
as 3.2% (22).
Additionally, platelet function was assessed by
ﬂow cytometric assessment of the phosphorylation
status of VASP and expressed as the platelet reactivity
index. The VASP platelet reactivity index was deter-
mined from blood samples sent with an isolated
ambient shipping system to a central corelaboratory (Center for Platelet Research Studies,
Boston Children’s Hospital, Boston, Massachusetts),
which was blinded to patient treatment group (23).
Samples were to be tested within 72 h (88% within 24
h). Between sample receipt and analysis on the day of
receipt, samples were stored at room temperature. All
samples were allowed to stand at room temperature
shielded from light for 30 min after staining before
analysis by ﬂow cytometry. Flow cytometric analysis
was performed between 30 and 90 min after
completion of staining.
STATISTICAL ANALYSIS. For intraindividual corre-
lation analyses, all patients with at least 2 platelet
function results at the same dose of clopidogrel and
with a drug compliance >80% on both occasions were
included. No imputation was applied for missing
data. Discrete variables are reported as percentage
and continuous variables as mean  SD. Paired dis-
crete variables were analyzed by a paired t test, and
paired categorical data by McNemar’s test unless
otherwise speciﬁed. In the 2-sided test, a p value
<0.05 was regarded as signiﬁcant. Cohen’s kappa
coefﬁcients were used to describe the agreement of
responder status between periods. The proportion of
individuals with a change in responder status was
evaluated using the alternative hypothesis of the
proportion exceeding 5%. The distributions of change
in platelet reactivity were generated, and SDs were
reported. Analyses were run in SAS software version
9.1.3 Service Pack 2 (SAS Institute, Cary, North
Carolina).
RESULTS
The mean age in the study population was 60.2  9.9
years, 75% were male, 57% had a history of myocar-
dial infarction, and 97% had a history of PCI. When
assessing patients with serial measurements, the
mean platelet reactivity as determined by the Ver-
ifyNow P2Y12 test and VASP assays did not differ
between serial sampling with the 75-mg and 150-mg
doses of clopidogrel (Table 1). Likewise, the total
proportion of nonresponders to clopidogrel did not
change between both periods at the same dose of
clopidogrel (Table 1).
In contrast, analyzing each patient individually,
15.7% of patients taking clopidogrel 75 mg had a
change in their nonresponder-status (PRU $230)
when tested at 2 different time points (Table 2). Based
on the coefﬁcient of variation of the assay used, only
2.9% of patients would have been expected to change
their nonresponder-status if platelet function would
be stable over time. Using the deﬁnition of PRU $208,
1 in 5 patients experienced a change in status with
TABLE 2
Periods
No
Deﬁnit
Period 2
Kappa ¼ 0
No
Deﬁnit
Period 2
Kappa ¼ 0
No
Deﬁnit
Period 2
Kappa ¼ 0
No
Deﬁnit
Period 2
Kappa ¼ 0
Values are n
Abbreviat
TABLE 1 Platelet Function Testing by Period
Period 1 Period 2 p Value
VerifyNow Assay (PRU)
75 mg 163.6  80.2 162.3  87.1 0.79
Nonresponder (PRU $230) 22.4 21.9 0.86
Nonresponder (PRU $208) 31.9 30.0 0.56
150 mg 127.0  82.5 125.4  79.8 0.69
Nonresponder (PRU $230) 11.5 11.5 1.00
Nonresponder (PRU $208) 16.3 16.3 1.00
VASP Assay (PRI)
75 mg 57.3  21.4 57.6  20.3 0.79
150 mg 46.7  21.0 47.0  20.8 0.78
Values are mean  SD or %.
PRI ¼ platelet reactivity index; PRU ¼ P2Y12 reaction unit(s); VASP ¼ vasodilator-stimulated
phosphoprotein.
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36475 mg. Cohen’s kappa yielded values between 0.44
and 0.54, suggesting only moderate agreement, and a
change in responder status was found in a signiﬁcant
proportion of patients irrespective of nonresponderShift Tables for the Individual Responder Status Change Between
75-mg Clopidogrel
nresponder
ion $ 230 PRU
Period 1
Responder Nonresponder Total
Responder 147 (70.0) 17 (8.1) 164 (78.1)
Nonresponder 16 (7.6) 30 (14.3) 46 (21.9)
Total 163 (77.6) 47 (22.4) 210 (100)
.544
nresponder
ion $ 208 PRU
Period 1
Responder Nonresponder Total
Responder 122 (58.1) 25 (11.9) 147 (70.0)
Nonresponder 21 (10.0) 42 (20.0) 63 (30.0)
Total 143 (68.1) 67 (31.9) 210 (100)
.488
150-mg Clopidogrel
nresponder
ion $ 230 PRU
Period 1
Responder Nonresponder Total
Responder 173 (82.8) 12 (5.7) 185 (88.5)
Nonresponder 12 (5.7) 12 (5.7) 24 (11.5)
Total 185 (88.5) 24 (11.5) 209 (100)
.435
nresponder
ion $ 208 PRU
Period 1
Responder Nonresponder Total
Responder 159 (76.1) 16 (7.7) 175 (83.7)
Nonresponder 16 (7.7) 18 (8.6) 34 (16.3)
Total 175 (83.7) 34 (16.3) 209 (100)
.438
(%).
ion as in Table 1.deﬁnition or tested dose of clopidogrel (p < 0.001 for
each) (Fig. 1). The number of patients changing from
responder to nonresponder status was similar to
the number of patients switching in the opposite
direction.
Because even a minor change in platelet reactivity
could alter the responder status (i.e., from 229 PRU
to 230 PRU), data were also analyzed in a continuous
fashion. The individual change in platelet reactivity
over time approximated a Gaussian distribution with
equal changes in both directions being found
(Fig. 2). Notably, the SDs for the change in platelet
reactivity over serial time points with the same
clopidogrel dose were 68 PRU for 75 mg and 59 PRU
for 150 mg. When analyzing various cutpoints
ranging from 80 to 20 PRU, between 15.8% and
63.8% of patients demonstrated a change in platelet
reactivity status over time, with parallel results seen
with the VASP assay (Table 3, Online Fig. B). The
number of patients with a given absolute change in
platelet reactivity was similar for both the 75-mg and
the 150-mg doses at all cutoffs.
Diabetes mellitus and body mass index were the
variables most consistently associated with a change
in platelet function over time across the assays and
doses of clopidogrel used (Online Table A).
DISCUSSION
A variable patient response to clopidogrel has been
demonstrated and high on-treatment platelet reac-
tivity, as measured by several different platelet
function tests, has been associated with ischemic
events (10,11). Additionally, low on-treatment plate-
let reactivity has been related to hemorrhagic
events (24). The present analysis of ELEVATE–TIMI
56 data demonstrates that, in a cohort, mean on-
treatment platelet reactivity did not differ over
time. However, on an individual basis, a signiﬁcant
number of patients exhibited discordant values
(Central Illustration), with approximately 1 in 5 pa-
tients experiencing a change in their clopidogrel
responder status over time, despite similar clinical
conditions. Importantly, the 150-mg dose of clopi-
dogrel was not able to overcome this degree of vari-
ability in serial platelet reactivity measurements.
These ﬁndings have implications for the potential
clinical implementation of these tests, as well as for
the design of future studies.
Some studies have demonstrated only minor
changes in platelet phenotype or nonresponder status
over time among patients treated with clopidogrel
(23,25,26). Other data have shown that platelet func-
tion in individual healthy subjects who are not on
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FIGURE 1 Proportion of Individuals With a Change in
Responder Status Between Periods
Values of p < 0.001 for all columns for testing the alternative
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stimulated phosphoprotein.
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365antiplatelet therapy can vary signiﬁcantly over time
(27,28). One study that enrolled patients undergoing
PCI reported that 27% of patients had a change in
nonresponder status within 1 month (29). These
latter ﬁndings, however, could have been explained
by the large proportion of patients with ACS at the
time of enrollment, a factor known to be associated
with poor response to clopidogrel (6), and the di-
rection of change was predominantly from nonre-
sponder to responder status, consistent with the
metabolic changes after ACS. Notably, even within
the stable population in ELEVATE–TIMI 56, 1 in 4
patients still experienced a change in PRU >60
while being treated with the same dose of clopi-
dogrel. This magnitude of change would, for
example, be sufﬁcient to shift an entire risk cate-
gory in a meta-analysis that assessed PRU quartiles
and rates of adverse cardiovascular outcomes (19).
Moreover, in the present study, despite being
treated with the same dose of clopidogrel, w40% of
patients had a change in PRU >40 with serial
sampling, which approximates the average PRU
difference caused by increasing the clopidogrel dose
from 75 mg to 150 mg.
The time-dependent variability in individual
platelet reactivity in ELEVATE–TIMI 56 was detected
even within the context of a carefully monitored,
double-blind clinical trial, with uniform assessment
of platelet function among stable patients with car-
diovascular disease. Additionally, the study con-
trolled for potential biasing factors such as drugcompliance, timing of the dose, and/or drugs inter-
acting with clopidogrel bioactivation. The variability
in platelet reactivity measurements would be ex-
pected to be even more pronounced in clinical
practice where such close monitoring and genetic
data might not be routine. We can only speculate
which mechanisms contribute to this intraindividual
variability. Potential factors might include either
true alterations in platelet reactivity due to ﬂuctua-
tions in platelet production and expression of
the P2Y12 receptor, changes in hepatic metabolism
altering the level of clopidogrel bioactivation, un-
recognized noncompliance, or artifactual changes in
measured platelet reactivity due to biological or
technical issues affecting the assay.
The signiﬁcant intraindividual variability in res-
ponse to antiplatelet therapy in a large proportion of
patients, as demonstrated by the present analysis,
could be integral for understanding the negative
results observed in 3 randomized trials that evalu-
ated the impact of personalized antiplatelet strate-
gies guided by platelet function testing on clinical
outcome (18,21,30). Two of these studies enrolled
stable patients, and 1 trial included patients with
and without ACS. In these studies, patients identi-
ﬁed as nonresponders to clopidogrel received
TABLE 3 Proportion of Individual Subjects With a Change in
Platelet Reactivity Between Periods by Clopidogrel Dose and Assay
75-mg Clopidogrel 150-mg Clopidogrel
VerifyNow Assay (change in PRU)
>20 PRU 63.8 (56.9–70.3) 61.7 (54.8–68.3)
>40 PRU 41.4 (34.7–48.4) 40.7 (33.9–47.7)
>60 PRU 28.6 (22.6–35.2) 24.9 (19.2–31.3)
>80 PRU 16.2 (11.5–21.9) 15.8 (11.1–21.5)
VASP assay (change in PRI)
>5 PRI 65.2 (58.4–71.7) 70.8 (64.1–76.9)
>10 PRI 42.4 (35.6–49.4) 52.2 (45.2–59.1)
>15 PRI 27.6 (21.7–34.2) 29.2 (23.1–35.9)
>20 PRI 20.5 (15.2–26.6) 18.7 (13.6–24.6)
Values are % (95% conﬁdence interval).
Abbreviations as in Table 1.
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366additional loading doses and higher maintenance
doses of clopidogrel (150 mg) or were switched to
prasugrel. Dose adjustment was mainly based on a
single platelet function test obtained early after the
initial loading dose of clopidogrel. In 1 trial, an
additional treatment adjustment was allowed, but
not mandatory, if a limited response to antiplatelet
therapy was found at 14 to 30 days after enrollment
(30). The main ﬁnding of all 3 trials was that
personalized antiplatelet treatment, compared with
standard treatment with clopidogrel 75 mg daily,
did not reduce major cardiovascular events. Several
potential reasons for these ﬁndings have beenCENTRAL ILLUSTRATION Measurements of Platelet Function Var
Distribution of platelet inhibition in patients on clopidogrel with the arrdiscussed such as limited effectiveness of the
intervention compared with the standard treatment
strategy (150 mg vs. 75 mg clopidogrel) and limited
power due to lower-than-expected event rates.
Given the results of the present analysis, intra-
individual variability in platelet phenotype might
have been another factor leading to these results
because strategies using only platelet function re-
sults from a single time point might not detect the
majority of patients with a suboptimal response to
clopidogrel.
STUDY LIMITATIONS. There are some limitations
to the present analysis. Each treatment period con-
sisted of w14 days. Although platelet phenotype
becomes more stable during long-term treatment,
this time frame allowed for a reasonable window to
achieve a steady-state antiplatelet effect with each
regimen, with no signiﬁcant carryover effect from
the previous treatment. Second, variability between
the timing of study drug administration and blood
sampling could have occurred, as well as non-
adherence. In an attempt to address these concerns,
sites and patients were instructed to draw samples
at trough levels and conduct pill counts. Third,
patients with the CYP2C19*2 loss-of-function poly-
morphism were not included in the present study
because they were not tested twice at the same
dose. Fourth, given the post-hoc design of the
present analysis, these data need conﬁrmation in
further studies. Finally, this trial cannot determiney Over Time in a Signiﬁcant Proportion of Patients
ows indicating individual changes in platelet inhibition over time.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Even while
maintaining a stable dose of clopidogrel, >40% of patients
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367the signiﬁcance of the intraindividual variability in
clinical practice because it was not powered for
clinical outcomes, and intraindividual variability
might be even greater in real life without the pre-
sent strict control for compliance and other factors
affecting the antiplatelet effect of clopidogrel. To
eliminate the documented alteration in platelet
reactivity that occurs in the setting of ACS, we
studied stable patients. The variability we observed,
assuming it would also be present in ACS patients,
also would be of clinical signiﬁcance in that high-
risk setting.exhibit variations in platelet reactivity similar to those caused
by doubling the dose from 75 to 150 mg daily.
TRANSLATIONAL OUTLOOK: In designing future studies that
use measurements of platelet inhibition in patients exposed to
clopidogrel, investigators should consider the limitations of
testing at a single time point and the value of serial data.CONCLUSIONS
Measurements of platelet reactivity vary over time
in a signiﬁcant proportion of patients, even when
higher maintenance doses of clopidogrel are used.
Based on these results, treatment adjustment ac-
cording to platelet function testing at a single timepoint might not be sufﬁcient for guiding antiplatelet
therapy in either clinical or research settings.
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